Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
20/05/2024 14:23
May 20 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS TO COLLABORATE WITH THE DANA-FARBER
CANCER
INSTITUTE ON AN INVESTIGATOR-SPONSORED PHASE 2 CLINICAL TRIAL
EVALUATING ZOTATIFIN AS COMBINATION TREATMENT IN ER+ ENDOMETRIAL
CANCER AND IN LOW GRADE SEROUS OVARIAN CANCER
* EFFECTOR THERAPEUTICS : ANTICIPATE DETERMINATION OF PHASE
2 DOSE
(RP2D) OF ZOTATIFIN IN COMBINATION WITH FULVESTRANT &
ABEMACICLIB, IN H2 2024
Source text for Eikon: ID:nGNX2DYMHP
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright